
## Frauke Christ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2193657/publications.pdf Version: 2024-02-01



FDALLER CHDIST

#	Article	IF	CITATIONS
1	LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators. Cancer Gene Therapy, 2022, 29, 133-140.	2.2	7
2	Design, synthesis, in silico studies, and antiproliferative evaluations of novel indolin-2-one derivatives containing 3-hydroxy-4-pyridinone fragment. Bioorganic and Medicinal Chemistry Letters, 2022, 70, 128784.	1.0	3
3	LEDGINs, Inhibitors of the Interaction Between HIV-1 Integrase and LEDGF/p75, Are Potent Antivirals with a Potential to Cure HIV Infection. Advances in Experimental Medicine and Biology, 2021, 1322, 97-114.	0.8	6
4	Towards a Functional Cure of HIV-1: Insight Into the Chromatin Landscape of the Provirus. Frontiers in Microbiology, 2021, 12, 636642.	1.5	9
5	GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	17
6	Role of Transportin-SR2 in HIV-1 Nuclear Import. Viruses, 2021, 13, 829.	1.5	6
7	Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. Cells, 2021, 10, 192.	1.8	5
8	CRISPR/Cas9-Induced Mutagenesis Corroborates the Role of Transportin-SR2 in HIV-1 Nuclear Import. Microbiology Spectrum, 2021, 9, e0133621.	1.2	3
9	Molecular Mechanism of LEDGF/p75 Dimerization. Structure, 2020, 28, 1288-1299.e7.	1.6	4
10	Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects. Cells, 2020, 9, 754.	1.8	23
11	Capsid-Labelled HIV To Investigate the Role of Capsid during Nuclear Import and Integration. Journal of Virology, 2020, 94, .	1.5	34
12	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. Frontiers in Chemistry, 2019, 7, 574.	1.8	32
13	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathogens, 2019, 15, e1007958.	2.1	22
14	Impact of LEDGIN treatment during virus production on residual HIV-1 transcription. Retrovirology, 2019, 16, 8.	0.9	22
15	Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection. Viruses, 2019, 11, 12.	1.5	26
16	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. Medicinal Chemistry, 2019, 15, 755-770.	0.7	22
17	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood, 2018, 131, blood-2017-05-786962.	0.6	32
18	Inhibitors of the integrase–transportin-SR2 interaction block HIV nuclear import. Retrovirology, 2018, 15, 5.	0.9	14

FRAUKE CHRIST

#	Article	IF	CITATIONS
19	Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7053-E7062.	3.3	27
20	N-terminal half of transportin SR2 interacts with HIV integrase. Journal of Biological Chemistry, 2017, 292, 9699-9710.	1.6	11
21	Protein–protein and protein–chromatin interactions of LEDGF/p75 as novel drug targets. Drug Discovery Today: Technologies, 2017, 24, 25-31.	4.0	21
22	Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection. Journal of Virus Eradication, 2017, 3, 7-14.	0.3	3
23	LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine, 2016, 8, 248-264.	2.7	90
24	Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry. Scientific Reports, 2016, 6, 36485.	1.6	28
25	2-hydroxyisoquinoline-1,3(2 H ,4 H )-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4. European Journal of Medicinal Chemistry, 2016, 117, 256-268.	2.6	11
26	Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia. Trends in Pharmacological Sciences, 2016, 37, 660-671.	4.0	8
27	Kuwanonâ€L as a New Allosteric HIVâ€1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation. ChemBioChem, 2015, 16, 2507-2512.	1.3	39
28	HIV-1 integrase inhibition: looking at cofactor interactions. Future Medicinal Chemistry, 2015, 7, 2407-2410.	1.1	9
29	Host factors for retroviral integration site selection. Trends in Biochemical Sciences, 2015, 40, 108-116.	3.7	83
30	Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif. Nature Communications, 2015, 6, 7968.	5.8	53
31	Optimization of rhodanine scaffold for the development of protein–protein interaction inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 3208-3214.	1.4	4
32	The HIV-1 Integrase Mutant R263A/K264A Is 2-fold Defective for TRN-SR2 Binding and Viral Nuclear Import. Journal of Biological Chemistry, 2014, 289, 25351-25361.	1.6	28
33	Structure of transportin SR2, a karyopherin involved in human disease, in complex with Ran. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 723-729.	0.4	11
34	Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. European Journal of Medicinal Chemistry, 2014, 78, 425-430.	2.6	17
35	Validation of host factors of HIV integration as novel drug targets for anti-HIV therapy. MedChemComm, 2014, 5, 314-320.	3.5	4
36	Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. Bioorganic and Medicinal Chemistry, 2014, 22, 5446-5453.	1.4	15

FRAUKE CHRIST

#	Article	IF	CITATIONS
37	A new potential approach to block HIV-1 replication via protein–protein interaction and strand-transfer inhibition. Bioorganic and Medicinal Chemistry, 2014, 22, 2269-2279.	1.4	17
38	The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology, 2013, 435, 102-109.	1.1	96
39	4-Substituted 2-Hydroxyisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i> )-diones as a Novel Class of HIV-1 Integrase Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 606-611.	1.3	52
40	Interaction of the HIV-1 Intasome with Transportin 3 Protein (TNPO3 or TRN-SR2). Journal of Biological Chemistry, 2012, 287, 34044-34058.	1.6	52
41	Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization. Antimicrobial Agents and Chemotherapy, 2012, 56, 4365-4374.	1.4	158
42	De novo design of small molecule inhibitors targeting the LEDGF/p75-HIVintegrase interaction. RSC Advances, 2012, 2, 974-984.	1.7	13
43	Interplay between HIV Entry and Transportin-SR2 Dependency. Retrovirology, 2011, 8, 7.	0.9	51
44	Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology, 2010, 6, 442-448.	3.9	428
45	Synthesis of new pyridazine derivatives as potential antiâ€HIVâ€1 agents. Journal of Heterocyclic Chemistry, 2009, 46, 1420-1424.	1.4	9
46	LEDGF/p75 and transportin-SR2 are cellular cofactors of HIV integrase and novel targets for antiviral therapy. HIV Therapy, 2009, 3, 171-188.	0.6	4
47	Transportin-SR2 Imports HIV into the Nucleus. Current Biology, 2008, 18, 1192-1202.	1.8	231
48	Lentiviral nuclear import: a complex interplay between virus and host. BioEssays, 2007, 29, 441-451.	1.2	42
49	The Interaction of LEDGF/p75 with Integrase Is Lentivirus-specific and Promotes DNA Binding. Journal of Biological Chemistry, 2005, 280, 17841-17847.	1.6	182